The provision of IV Sedation is governed by the IACSD standards 2020 which limits primary care sedation to mainly benzodiazepine based sedation. This can be hard to manage and deliver for longer implant cases so sometimes a secondary care GA drug Propofol is used, with a narrower margin of safety. In this presentation I will discuss 4 hours plus sedation for full arch implant treatment using a new drug Remimazolam, which gives a more predictable and controllable sedation with rapid predictable clean recovery.